Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AOC1 | P19801 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.41 |
| ▸ | HRH1 | P35367 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034963 | 0.90 | HRH3 (0.54) | HRH3TDP1L3MBTL1AOC1AOC3 | |
| SCHEMBL6034811 | 0.80 | AOC1 (0.53) | HRH3TDP1L3MBTL1AOC1AOC3 | |
| SCHEMBL29939247 | 0.80 | AOC1 (0.53) | HRH3TDP1L3MBTL1AOC1AOC3 | |
| SCHEMBL14875584 | 0.79 | CACNA1B (0.52) | HRH3TDP1L3MBTL1AOC1AOC3 | |
| SCHEMBL6034796 | 0.74 | CHRNA7 (0.42) | HRH3TDP1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL4793724 | 0.73 | HRH3 (0.79) | HRH3TDP1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL3873265 | 0.72 | EHMT2 (0.44) | HRH3TDP1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL294034 | 0.71 | AOC1 (0.55) | TDP1L3MBTL1AOC1AOC3CYP1A2 | |
| SCHEMBL11337893 | 0.71 | SIGMAR1 (0.60) | HRH3SIGMAR1HRH1LTA4H | |
| SCHEMBL28900212 | 0.71 | SIGMAR1 (0.51) | HRH3SIGMAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | HRH3 102/4885TDP1 1566/4885L3MBTL1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.